Literature DB >> 1906658

In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a.

W de Riese1, E Allhoff, C G Stief, G Lenis, R Schlick, S Liedke, P Anton, U Jonas.   

Abstract

Samples of 38 human renal cell carcinomas (RCC) were subjected to routine histopathological examination but also to in vitro sensitivity testing with mitomycin C, vinblastine and interferon Alpha-2a at various concentrations corresponding to serum titers recommended to be effective in vivo, employing a monolayer assay. Extending earlier in vitro studies, both tumor cell kill rates (TCKR) and proliferation rates (PR) were assessed. Following in vitro preparation the tumor cell cultures were simultaneously exposed to the anticancer drugs listed above. The proliferation rates were determined immunocytochemically using the monoclonal antibody Ki-67. Nine (23.7%) of the tumors investigated revealed temporary and limited response with respect to either TCKR or PR. Improvement of this percentage could only be obtained by increasing drug concentration to titers with toxicity intolerable for in vivo administration. The in vivo data presented correspond to clinical temporary and limited remissions in patients with metastatic RCC ranging up to 25%.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906658     DOI: 10.1007/bf00368182

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  19 in total

1.  Re: Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma.

Authors:  W H Davis
Journal:  J Urol       Date:  1989-01       Impact factor: 7.450

Review 2.  Therapeutic options in renal cell carcinoma.

Authors:  A C Buzaid; M B Todd
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

3.  Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer.

Authors:  J P Bergerat; R Herbrecht; P Dufour; D Jacqmin; C Bollack; G Prevot; G Bailly; S de Garis; F Juraschek; F Oberling
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

Review 5.  Interferon therapy of metastatic renal cell cancer.

Authors:  H B Muss
Journal:  Semin Surg Oncol       Date:  1988

6.  Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy.

Authors:  M Albrecht; W E Simon; F Hölzel
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

7.  Phase I/II trial of interferon-beta-serine in patients with renal cell carcinoma: immunological and biological effects.

Authors:  J J Rinehart; D Young; J Laforge; D Colborn; J A Neidhart
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

8.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Authors:  J U Gutterman; S Fine; J Quesada; S J Horning; J F Levine; R Alexanian; L Bernhardt; M Kramer; H Spiegel; W Colburn; P Trown; T Merigan; Z Dziewanowski
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

Review 9.  In vitro predictive testing: the sulfonamide era.

Authors:  D D Von Hoff
Journal:  Int J Cell Cloning       Date:  1987-05

10.  An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery.

Authors:  J Gerdes
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

View more
  2 in total

1.  Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.

Authors:  S Küpeli; M Beksac; B Küpeli; S Baltaci; O Süzer
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

2.  Effects of cytokines on growth in vitro of primary human renal cell carcinoma.

Authors:  W de Riese; E P Allhoff; M Werner; C G Stief; S Liedke; H Kirchner; J Atzpodien
Journal:  Urol Res       Date:  1992
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.